Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golcadomide + R-CHOP versus placebo + R-CHOP in previously untreated high-risk large B-cell lymphoma
CTR20242203Phase 3Active
- Sponsor
- Celgene Corporation
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of golcadomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Celgene Corporation. Started Sep 2024; status: active.
02
Drugs
golcadomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20242203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242203.